Medplus Health Services Ltd logo

Medplus Health Services Ltd

MEDPLUS NSE

Key Fundamentals

MicrocapPharmacy RetailRetail
Market Cap
₹7,886 Cr
Volatility
Low Risk
P/E Ratio
37.9
EBITDA
₹679 Cr
Return on Equity
11.12%
Debt to Equity
0.72
Book Value
₹164.43
EPS
₹6.36
52W High
₹1,022.2
52W Low
₹653

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Medplus Health Services Ltd insights

44 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has delivered good profit growth of 28.2% CAGR over last 5 years

Weaknesses

4
  • Stock is trading at 3.99 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 8.35% over last 3 years.
  • Promoters have pledged 60.7% of their holding.

Growth Rate

Revenue Growth
12.60% ↗
Net Income Growth
46.21% ↗
Cash Flow Change
-8.30% ↘
ROE
28.85% ↗
ROCE
18.79% ↗
EBITDA Margin (Avg.)
12.59% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 18d ago
AI opinion · based on fundamentals
Risk high

Medplus Health Services trades at a market cap of ₹8,601 Cr with a PE of 40.8x and has delivered 18% compounded sales growth over 5 years, but the stock has declined 23% over the past year while promoters have pledged 60.7% of their holding.

Bull Case 7
  • Strong 5-year compounded profit growth of 28% CAGR indicates improving profitability as the pharmacy retail chain scales
  • TTM sales growth of 17% demonstrates continued top-line momentum in a defensive healthcare retail segment
  • 5-year compounded sales CAGR of 18% reflects consistent store expansion and same-store sales growth
  • Last year ROE improved to 12%, up from the 3-year average of 8%, suggesting improving capital efficiency
  • 3-year compounded profit CAGR of 66% shows rapid earnings acceleration from operating leverage on the growing store base
  • 10-year compounded profit CAGR of 37% demonstrates a long track record of earnings compounding
  • Pharmacy retail is a defensive, non-discretionary sector with structural tailwinds from India's aging demographics and rising healthcare spend
Bear Case 8
  • Promoters have pledged 60.7% of their holding, creating significant risk of forced selling or loss of control in a downturn
  • PE of 40.8x is expensive relative to 3-year average ROE of just 8%, implying the market is pricing in growth that may not materialize proportionally
  • Stock has declined 23% over the past 1 year, reflecting negative market sentiment and possible derating
  • 3-year stock CAGR of -9% shows sustained underperformance despite strong profit growth, suggesting valuation compression
  • Zero dividend yield despite repeated profitability indicates no capital return to shareholders
  • Price-to-book of 4.35x is elevated for a company generating only 8% ROE over 3 years, implying poor return on reinvested capital relative to valuation
  • 3-year average ROE of 8% is below cost of equity for most frameworks, questioning value creation for shareholders
  • High promoter pledge of 60.7% combined with stock price decline of 23% in one year raises margin call risk

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 15d ago
Headwinds 3
  • Q1FY27 net profit drops 21.7% Jul 21

    Consolidated net profit fell to ₹331.67 million from ₹423.57 million YoY in Q1FY27, despite revenue growth of 21.8%.

  • Subsidiary store licenses suspended Jul 15

    Optival Health Solutions received drug license suspensions for three stores in Karnataka under the Drugs and Cosmetics Act, with an additional two-day suspension for a Bijapur store on Jul 27. Combined estimated revenue impact is ₹1.88 lakh.

  • CAPEX plans put on hold Jul 23

    Board kept previously approved CAPEX plans in abeyance, affecting a Food Park and a health facility in Hyderabad, signaling near-term growth investment slowdown.

Positives 1
  • Revenue grows 21.8% YoY Jul 21

    Q1FY27 revenue from operations rose 21.8% to ₹18,796 million, indicating strong top-line momentum despite profit decline.

Neutral 5
  • 17.27% stake pledge corrected Aug 1

    Catalyst Trusteeship corrected the pledge date for 49 lakh shares (17.27% voting capital) from June 24 to July 24, 2026. Pledge quantum unchanged.

  • 20th AGM scheduled Aug 17 Jul 22

    MedPlus will hold its 20th AGM on August 17, 2026 via video conferencing, with remote e-voting available until August 10.

  • BRSR filed for FY 2025-26 Jul 23

    MedPlus submitted its Business Responsibility and Sustainability Report for FY 2025-26, disclosing ESG practices and governance frameworks.

  • Investor presentation filing corrected Jul 22

    Company asked exchanges to disregard an inadvertent filing from July 21 and replaced it with the correct investor presentation.

  • Earnings call hosted Jul 22 Jul 15

    MedPlus scheduled and held an earnings call on July 22, 2026 to discuss Q1FY27 financial results.

TL;DR: MedPlus is delivering strong revenue growth at 21.8% YoY, but profitability is under pressure with net profit declining 21.7% in Q1FY27, suggesting margin compression. CAPEX plans on hold and minor regulatory actions on subsidiary stores add to near-term uncertainty. The trend is mixed — top-line expansion is healthy but investors should watch whether margin recovery materializes in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,284
1,409
1,441
1,490
1,489
1,576
1,561
1,510
1,543
1,679
1,806
1,864
1,880
Expenses
1,213
1,324
1,350
1,385
1,395
1,452
1,429
1,373
1,412
1,530
1,648
1,695
1,746
Operating Profit
71
85
92
106
94
124
133
136
131
149
159
169
133
OPM %
6%
6%
6%
7%
6%
8%
8%
9%
8%
9%
9%
9%
7%
Other Income
9
10
10
10
9
12
13
16
15
17
18
21
20
Interest
23
24
24
25
25
25
26
27
27
29
31
33
33
Depreciation
52
55
57
59
60
63
62
64
66
69
73
76
78
PBT
5
16
20
32
18
48
57
61
53
69
73
80
42
Tax %
26%
12%
31%
-5%
19%
19%
19%
16%
20%
19%
21%
20%
21%
Net Profit
4
15
14
34
14
39
46
51
42
56
58
64
33
EPS in Rs
0.32
1.22
1.15
2.79
1.2
3.24
3.83
4.29
3.54
4.63
4.82
5.33
2.76
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,368
1,733
2,011
2,131
2,273
2,871
3,069
3,779
4,558
5,625
6,136
6,892
7,229
Expenses
1,336
1,696
1,940
2,073
2,153
2,737
2,852
3,507
4,292
5,270
5,648
6,284
6,620
Operating Profit
32
37
71
58
120
134
217
273
266
355
488
608
610
OPM %
2.4%
2.1%
3.5%
2.7%
5%
4.7%
7%
7%
6%
6%
8%
9%
8%
Other Income
4
8
7
8
11
17
21
31
46
40
48
71
76
Interest
14
17
19
28
50
47
55
66
83
96
103
120
126
Depreciation
9
10
11
12
59
75
88
119
182
224
250
283
295
PBT
14
19
48
26
23
29
95
118
47
73
183
275
264
Tax %
46%
52%
40%
-65%
48%
94%
34%
20%
-6%
11%
18%
20%
—
Net Profit
7
9
29
42
12
2
63
95
50
66
150
220
210
EPS in Rs
419
509
1,621
2,080
585
107
1,393
8.03
4.17
5.48
12.56
18.3
17.54
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.17
0.17
0.17
0.19
0.19
0.19
0.45
24
24
24
24
24
Reserves
141
137
148
303
291
528
730
1,394
1,467
1,554
1,717
1,951
Borrowings
170
223
204
162
429
477
590
815
900
1,010
1,120
1,424
Other Liabilities
126
149
183
179
239
344
245
361
406
417
500
533
Total Liabilities
438
509
535
644
959
1,349
1,566
2,594
2,797
3,005
3,360
3,933
Fixed Assets
67
77
81
83
377
419
517
799
1,138
1,242
1,296
1,595
CWIP
3
3
2
1
1
5
6
20
25
11
16
32
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
368
429
453
560
580
924
1,043
1,775
1,633
1,752
2,047
2,306
Total Assets
438
509
535
644
959
1,349
1,566
2,594
2,797
3,005
3,360
3,933
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-19
-17
34
32
147
-7
3
170
90
144
540
496
Investing
-16
-32
-15
-18
-19
-28
-35
-703
429
-83
-318
-128
Financing
67
35
-29
-1
-83
90
-6
440
-170
-198
-228
-256
Net Cash Flow
32
-15
-10
14
45
56
-37
-93
350
-137
-5
112
Free Cash Flow
-35
-35
19
32
125
-37
-51
56
-78
61
482
373
CFO/OP
-26
-19
70
96
133
6
15
75
39
49
120
94
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1
1
0
2
1
1
1
1
1
1
1
1
Inventory Days
84
82
76
76
78
101
113
112
117
111
106
99
Days Payable
34
29
25
27
31
37
22
30
27
21
24
22
Cash Conversion Cycle
51
53
51
51
48
65
91
82
91
92
83
79
Working Capital Days
16
12
14
13
8
25
46
100
58
58
54
49
ROCE %
—
11%
19%
13%
12%
9%
13%
10%
5%
7%
10%
13%

Shareholding Pattern

As of Jun 2026
Promoters 40.19%
DIIs 29.95%
FIIs 14.38%
Public 10.90%
Others 4.58%
Total 100.00%
  Aug 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
96.68%
40.43%
40.43%
40.43%
40.43%
40.43%
40.43%
40.43%
40.41%
40.45%
40.39%
40.39%
40.39%
40.39%
40.34%
40.32%
40.29%
40.29%
40.22%
40.19%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
12.36%
0.00%
14.94%
14.85%
14.72%
15.23%
15.61%
16.42%
16.54%
16.83%
15.53%
14.38%
DIIs
0.00%
11.61%
11.99%
14.96%
14.31%
28.77%
28.16%
13.62%
25.49%
16.28%
22.47%
22.17%
27.97%
25.65%
26.19%
26.04%
26.52%
26.57%
27.82%
29.95%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
0.00%
6.38%
5.83%
5.88%
6.22%
6.21%
6.13%
5.83%
6.40%
6.15%
7.30%
7.56%
11.84%
13.21%
13.10%
12.59%
12.22%
11.88%
11.82%
10.90%
Others
3.32%
41.58%
41.75%
38.73%
39.05%
24.59%
25.28%
40.12%
15.33%
37.12%
14.90%
15.03%
5.07%
5.52%
4.77%
4.64%
4.43%
4.42%
4.62%
4.58%
No. of Shareholders
69
3,42,917
82,627
77,119
76,972
74,702
73,512
70,017
66,430
66,048
74,976
76,934
87,328
83,912
83,439
81,742
78,337
79,157
77,278
76,005

Documents

Frequently Asked Questions about Medplus Health Services Ltd

Where is Medplus Health Services Ltd (MEDPLUS) listed?
Medplus Health Services Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDPLUS and BSE: 543427. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Medplus Health Services Ltd belong to?
Medplus Health Services Ltd operates in the Retail sector within the Pharmacy Retail industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Medplus Health Services Ltd?
Medplus Health Services Ltd has a market capitalisation of approximately ₹7886.40 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Medplus Health Services Ltd?
The Price-to-Earnings (PE) ratio of Medplus Health Services Ltd is 37.90. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Medplus Health Services Ltd?
Over the past 52 weeks, Medplus Health Services Ltd has traded between a low of ₹653 and a high of ₹1,022.2. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Medplus Health Services Ltd?
Medplus Health Services Ltd has a Return on Equity (ROE) of 11.12%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Medplus Health Services Ltd on Tapetide?
On Tapetide, you can view Medplus Health Services Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Website medplusindia.com
Listed 2021-12-23
Face Value ₹ 2
Issued Size 11,98,22,581

Explore More

More in Retail → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List